

July 6, 2021 Web Announcement 2541

<u>Attention Provider Types 20 (Physician, M.D., Osteopath, D.O.), 24 (Advanced Practice Registered Nurse), 74 (Nurse Midwife), and 77 (Physician Assistant):</u>

DEA X-Waiver Providers Prescribing Buprenorphine

The Division of Health Care Financing and Policy (DHCFP) is requesting participation in a Public Hearing on July 27, 2021, for providers and the public regarding recently updated guidance. On April 28, 2021, the Department of Health and Human Services issued updated guidance for DEA X-waiver providers prescribing buprenorphine. Federal Register: Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Specifically, this exemption allows these practitioners to treat up to 30 patients with Opioid Use Disorder (OUD) using buprenorphine without having to make certain training-related certifications and without certifying their capacity to provide counseling and ancillary services. Providers are still required to submit an application designated as a "Notice of Intent" in order to prescribe buprenorphine for the treatment of OUD.

This guidance exempts the following provider types from the certification requirements related to training, counseling, and other ancillary services (i.e., psychosocial services) under 21 U.S.C. 823(g)(2)(B)(i)-(ii).:

- Eligible physicians (PT 20)
- Physician assistants (PT 77)
- Advance practice registered nurse (PT 24)
- Nurse midwives (PT 74)

In order to align current Medication Assisted Treatment (MAT) policy with the updated guidance, DHCFP is updating Medicaid Services Manual (MSM) Chapter 3800 Medication Assisted Treatment. The proposed language will be presented at the Medical Care Advisory Meeting on July 13, 2021. The proposed changes to MSM 3800 will be heard at the Public Hearing on July 27, 2021. Providers and members of the public are invited to attend and provide feedback.

For questions, please send an email to: BehavioralHealth@dhcfp.nv.gov